Initial Launch Execution Fails to Impress for Biogen’s Aduhelm – the First-to-Market Disease-Modifying Therapy for the Treatment of Alzheimer’s Disease – as the Controversy Churn Continues, According to Spherix Global Insights
- Wednesday, July 14, 2021, 7:02
- Finance
- Add a comment
EXTON, Pa., July 14, 2021 /PRNewswire/ — As expected with the recent media maelstrom surrounding its June 7th approval, unaided and aided awareness of Biogen’s Aduhelm, the first disease-modifying therapy (DMT) for the treatment of Alzheimer’s disease, is almost ubiquitous among US…
About the Author
adminasapcorp has written 41782 stories on this site.